Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative Neoplasms

Abstract excerpt

Myelofibrosis (MF; either primary or postpolycythemia vera/ essential thrombocythemia) is a chronic and debilitating myeloproliferative neoplasm (MPN) for which there is no well-accepted therapeutic standard of care. Clinical signs of this disease, cytopenias (primarily anemia), splenomegaly, and constitutional symptoms (eg, hypercatabolic state, fatigue, night sweats, fever, bone pain) create significant...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Kruppel-like factors research
• Share to Myeloproliferative Neoplasms: Diagnosis and Treatment